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INTRODUCTION 
In 1957, a growth hormone-dependent 
factor was discovered, which could affect the 
increase of growth of the epiphyseal cartilage. 
A more general expression "somatomedine" 
was presented from various metabolic effects 
and the insulin-like nature view.
1 
They have a 
high structural homology with insulin. They 
were renamed as Insulin-like growth factor 1 
and 2.
2
 IGF-1 is known as Somatomedin C, is 
produced in the liver and is responsible for cell 
differentiation, transformation, suppression of 
apoptosis, cell cycle progression, cell 
proliferation and differentiation, nervous 
system and muscular system and internal 
secretion.
3
 IGF-1 recombinant protein plays a 
role in the treatment of many diseases. The 
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ABSTRACT 
Background and aims: Laron syndrome is a disease that treated by Insulin-like Growth 
Factor 1 (IGF-1). This protein is a single chain and has three disulfide bonds. People with 
Laron syndrome have low rates of cancer and diabetes, although they appear to be at 
increased risk of casual death due to their stature. IGF-1 is synthesized by many tissues 
and is secreted from liver as an endocrine hormone which is transmitted to other tissues. 
IGF-1 is responsible for cell differentiation, transformation, suppression of apoptosis, cell 
cycle progression, cell proliferation and differentiation. Expression system, the igf-1 
gene, codon adaptation index (CAI) and GC contents are very critical for the large scale 
production of this protein. Current study was aimed to Optimization and Construction of 
human IGF-1 gene in E. coli DH5α. 
Methods: we used DNA2 and ProtParam softwares for designing the best form to 
produce IGF-1. First, the coding sequence was verified and then synthesized. For 
confirmation of the pUC18-IGF-1, sequencing test was carried out using M13 reverse 
primer. Finally it was inserted into the cloning site of pUC18. 
Results: After coding optimization, the CAI rate was increased from 84 % to 90% and 
GC content from 55.07 % to 56.62%. The presence of the band near 225bp resulted from 
enzymatic digestion with 2 restriction enzymes demonstrates the correct cloning of the 
recombinant vectors in the cloning site of pUC18 cloning vector. 
Conclusion: According to software and experimental analysis, the designed sequence 
probably in the best form could be used for production of recombinant protein. 
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use of its system in diseases related to such as 
severe shortage of primary IGF, like Laron 
syndrome, reduced effect of growth hormone, 
idiopathic short stature, wasting syndrome.
4
 
The most of reported cases of Laron syndrome 
have been in people with Semitic origins. 
There is also a disproportionate number of 
sufferers found in remote villages in the South 
American country of Ecuador who are 
descended from colonial-era Jewish-origin 
New Christian conversos who had covertly 
migrated to Ecuador during the Spanish 
Conquest despite the Spanish Crown's 
prohibition of their immigration to its colonies 
and territories as a result of the Inquisition.
5,6 
Other patients include people of other Semitic 
non-Jewish origins, including from Saudi 
Arabia. Recent publications have proposed 
that Homo floresiensis showed a population 
with prevalent Laron syndrome.
7
 For large-
scale production of these proteins, engineered 
bacteria can be used.
8
 To do this, to increase 
the efficiency of protein expression, IGF-1 
gene sequence should be optimized in the used 
host bacteria.
9
 E. coli DH5α Bacteria is one of 
the engineered strains which is compatible 
with pUC cloning vectors.
10
 In this descriptive 
study, we obtain GC amount and CAI (codon 
adaptation index) using available software to 
design this protein. Then after designing and 
its synthesis, after cloning in the E. coli DH5α 
bacteria we sequence it. 
 
METHODS 
At first, we obtained the main sequence 
of amino acids in IGF-1 protein from the 
NCBI website. Then, functional section which 
is the CDS can be achieved by removal of the 
signalling sequence and the protein sections 
that does not have function. This section has 
70 functional amino acids. After that, we 
design 2 limiting position (restriction site) of 
the NdeI and BamHI-HF enzymes at the  
N-terminal and C-terminal. We optimized 
nucleotide sequence using DNA2 software. 
This optimizing is done to select the codons 
that are used more in the bacteria. The 
chromatogram sequencing was done also to 
that. We also determine the GC% content. 
ProtParam software was used for the stability 
of the recombinant protein. Optimized gene 
synthesis was done. Synthesized fragment 
length was 225 bp. This gene was received in 
the pUC18 cloning plasmid. The sequence of 
the gene was sequenced by contig method. 
Then, after receiving the plasmid carries the 
gene, it was transformed by CaCl2 and heat 
shock to the cloning bacteria. Since this 
bacterium is ampicillin plasmid resistant, 
colonies that were grown in the antibiotics 
culture can be selected. Then, reproduced 
plasmids were extracted using Qiagen 
Company plasmid extraction kit. Then, after 
confirming of the gene amplification on 1% 
agarose gel, with two NdeI and BamHI-HF 
enzymes of Biolab Company, enzyme 
digestion reaction was performed on this 
plasmid. Enzyme digestion was performed to 
confirm the correct cloning in the cloning 
bacteria. After cutting the designed fragment, 
pUC18 plasmid made linear using the 
mentioned enzymes. Then, the cut fragment 
and the linear vector were isolated on 1% 
agarose gel. 
 
RESULTS 
Gene optimization was carried in the  
E. coli host and the CAI and GC content were 
obtained as follows (Figures 1,2,3,4). 
 
Figure 1: CAI before optimization 
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Figure 2: CAI after optimization 
 
 
Figure 3: GC content before optimization 
optimization 
 
Figure 4: GC content after 
 
Figure 5: Sequence chromatogram 
Then after gene optimization it was 
transformed into the cloning E. coli DH5α 
bacteria. 
After White-blue colonies screening and 
Plasmids extraction, electrophoresis was done 
on 1% agarose gel, a band with a molecular 
weight of 2659 indicates the cloning plasmid 
with the considered gene (Figure 6). 
 
 
Figure 6: pUC18-IGF-1 with 2659 bp on 
1% agarose gel 
3000bp 
2500bp 
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Figure 7: sequencing of IGF-1 
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Table 1: IGF-1 gene before and after optimization 
 
 
Then, sequencing was done by contig 
method in order to the accuracy of gene 
cloning by reverse M13 primer (Figure 7). 
 
DISCUSSION 
Human insulin-like growth factor type 1 
is responsible for the increase of growth in the 
body.
11
 People lacking this growth factor have 
disease with defects in IGF-1 like Laron.
12
 In 
addition, this growth factor also is used for 
wound healing and the treatment of diabetes 
type 1 and 2.
13
 E. coli DH5α bacteria is one of 
the engineered strains to reproduce the gene. 
Beta galactosidase incomplete form (lacZ 
ΔM15) is designed in the genome of this 
bacteria that using α-complentation can be 
screened the pUC cloning vector using white-
blue colonies. pUC cloning vector has an 
ampicillin resistance gene for easy 
screening.
14 
In previous studies, it has been 
shown that cloning of the gene in E. coli 
bacteria optimization is needed. Since the 
objective of this project is amplification of this 
gene in bacteria with maximum efficiency to 
be performed, optimization of this gene using 
appropriate Bioinformatics software as well as 
studying protein expression in them is needed. 
At the end of this gene cutting site was 
designed for 2 NdeI and BamHI-HF cutting 
enzyme. TGA sequence was selected for the 
terminal codon. Nucleotide sequence of the 
recombinant protein was optimized by DNA2 
software. Using this software Codon 
Adaptation Index (CAI) and GC content of the 
coding were evaluated. If CAI results be more 
close to 100 percent it will be more suitable 
for expression in the host. The second case is 
GC content of the sequence. The more GC 
percent, the more energy for opening 2 DNA 
strings. So, it is better that GC content be 70 
percent. Recombinant sequence CAI was 84% 
prior to optimization in the normal condition 
of the gene which was improved to the 
reasonable rate of 90% and GC increased 
from 55.07 to 56.62 percent. ProtParam 
Software was used to determine protein 
stability. Also identification of gene cloning 
was confirmed by electrophoresis on 1% 
agarose gel. 
 
CONCLUSION 
This study is related to design, 
optimization and production of recombinant 
vector containing encoding fragment of 
human type 1 insulin-like growth factor. 
Having CAI= 90%, we could achieve the 
highest expression rate of this gene in E. coli 
bacteria. 
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